BrainStorm Cell Therapeutics GAAP EPS of -$0.19 beats by $0.17
Source: SeekingAlpha
2026-05-15 17:27:59 ET
More on BrainStorm Cell Therapeutics
- Brainstorm Cell secures $1M strategic financing
- Seeking Alpha’s Quant Rating on BrainStorm Cell Therapeutics
- Historical earnings data for BrainStorm Cell Therapeutics
- Financial information for BrainStorm Cell Therapeutics
Read the full article on Seeking Alpha
For further details see:
BrainStorm Cell Therapeutics GAAP EPS of -$0.19 beats by $0.17
Brainstorm Cell Therapeutics Inc.
NASDAQ: BCLI
BCLI Trading
6.0% G/L:
$0.95 Last:
12,999 Volume:
$0.95 Open:
BCLI Latest News
June 02, 2026 09:00:00 am
BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine
May 28, 2026 07:45:00 am
BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors
$6,179,474
9,804,398
11.34%
6
566390%
Biotechnology & Life Sciences
Healthcare
US
New York
